Literature DB >> 8477415

Increased projection of MHC and tumor antigens in murine B16-BL6 melanoma induced by hydrostatic pressure and chemical crosslinking.

V Ramakrishna1, A Eisenthal, Y Skornick, M Shinitzky.   

Abstract

The B16-BL6 melanoma, like most spontaneously arising tumors, is poorly immunogenic and expresses low levels of major histocompatibility complex (MHC) antigens. Treatment of cells of this tumor in vitro by hydrostatic pressure in the presence of adenosine 2',3'-dialdehyde (oxAdo), a membrane-impermeant crosslinker, caused elevated projection of MHC and a specific tumor antigen as demonstrated by flow-cytometric analysis. Maximum projection of both the MHC and the tumor antigens could be reached by application of 1200 atm for 15 min in the presence of 20 mM oxAdo. It is not yet clear whether this passive increase in availability of antigens on the cell surface originated from a dormant pool of antigens in the plasma membrane or from pressure-induced fusion of antigen-rich intracellular organelles (e.g. the endoplasmic reticulum). The immunogenic properties of the antigen-enriched B16-BL6 cells are described in the following paper.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8477415     DOI: 10.1007/bf01741167

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  42 in total

1.  Characterization of IL-2-induced murine cells which exhibit ADCC activity.

Authors:  A Eisenthal; E Shiloni; S A Rosenberg
Journal:  Cell Immunol       Date:  1988-09       Impact factor: 4.868

Review 2.  Cross-linking of CD4 and CD8 with the T-cell receptor complex: quaternary complex formation and T-cell repertoire selection.

Authors:  F Emmrich
Journal:  Immunol Today       Date:  1988-10

3.  The selection and characterization of an invasive variant of the B16 melanoma.

Authors:  I R Hart
Journal:  Am J Pathol       Date:  1979-12       Impact factor: 4.307

4.  Increased sensitivity to MHC-nonrestricted lysis of BL6 melanoma cells by transfection with class I H-2Kb gene.

Authors:  E Gorelik; G Jay; B Kwiatkowski; R B Herberman
Journal:  J Immunol       Date:  1990-09-01       Impact factor: 5.422

5.  Expression and modulation of a retrovirus-associated antigen by murine melanoma cells.

Authors:  S P Leong; J Muller; R A Yetter; E Gorelik; T Takami; V J Hearing
Journal:  Cancer Res       Date:  1988-09-01       Impact factor: 12.701

6.  Active immunotherapy of human solid tumor with autologous cells treated with cholesteryl hemisuccinate. A Phase I study.

Authors:  Y G Skornick; G H Rong; W F Sindelar; L Richert; J M Klausner; R R Rozin; M Shinitzky
Journal:  Cancer       Date:  1986-08-01       Impact factor: 6.860

7.  Inhibition of growth and metastases in mice by immunization with cholesterol hemisuccinate-enriched tumor cells.

Authors:  Y Skornick; E Gorelik; J Klausner; M Shinitzky; W F Sindelar
Journal:  Cancer Lett       Date:  1984-12       Impact factor: 8.679

8.  Abrogation of metastatic properties of tumour cells by de novo expression of H-2K antigens following H-2 gene transfection.

Authors:  R Wallich; N Bulbuc; G J Hämmerling; S Katzav; S Segal; M Feldman
Journal:  Nature       Date:  1985 May 23-29       Impact factor: 49.962

9.  Changes in cell-surface expression of MHC and Thy-1.2 determinants following treatment with lipid modulating agents.

Authors:  C P Muller; D A Stephany; M Shinitzky; J R Wunderlich
Journal:  J Immunol       Date:  1983-09       Impact factor: 5.422

10.  Presence on a human melanoma of multiple antigens recognized by autologous CTL.

Authors:  B Van den Eynde; P Hainaut; M Hérin; A Knuth; C Lemoine; P Weynants; P van der Bruggen; R Fauchet; T Boon
Journal:  Int J Cancer       Date:  1989-10-15       Impact factor: 7.396

View more
  1 in total

1.  Induction of cell-mediated immunity against B16-BL6 melanoma in mice vaccinated with cells modified by hydrostatic pressure and chemical crosslinking.

Authors:  A Eisenthal; V Ramakrishna; Y Skornick; M Shinitzky
Journal:  Cancer Immunol Immunother       Date:  1993-05       Impact factor: 6.968

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.